Literature DB >> 31689708

Insulin Action in the Hypothalamus Increases Second-Phase Insulin Secretion in Humans.

Martin Heni1,2,3, Robert Wagner4,5,6, Caroline Willmann4,5,6, Benjamin Assad Jaghutriz4,5,6, Andreas Vosseler4,5,6, Christian Kübler4,5,6, Verena Hund7, Klaus Scheffler8,9, Andreas Peter4,5,6, Hans-Ulrich Häring4,5,6, Hubert Preissl4,5,6,10,11,12, Stephanie Kullmann5,6, Andreas Fritsche4,5,6.   

Abstract

BACKGROUND: Animal studies and initial correlative data in humans indicate that insulin action in the brain may affect pancreatic insulin secretion. An important brain region for this process is the hypothalamus, an area that can develop insulin resistance.
METHODS: Fifteen young, healthy men (27 ± 3 years) with a wide BMI spectrum (20-30 kg/m2) underwent 2 hyperglycemic clamps (target blood glucose: 10 mmol/L). In this double-blind study, subjects received 160 U of insulin or placebo as a nasal spray on 2 days in randomized order. On another day, insulin sensitivity of the hypothalamus was determined by functional magnetic resonance imaging.
RESULTS: Glucose levels were comparable on both study days. In the whole group, C-peptide levels were not significantly different between conditions. Though, there was a significant interaction between insulin sensitivity of the hypothalamus × nasal spray × time on C-peptide levels (p = 10-6). The group was therefore divided according to median hypothalamic insulin sensitivity. C-peptide concentrations were higher after intranasal insulin compared to placebo spray in the group with a strong hypothalamic insulin response (p < 0.0001, β = 6.00 ± 1.24) and lower in the brain insulin-resistant group (p = 0.005, β = -2.68 ± 0.95). Neither somatostatin nor glucagon kinetics was altered by the nasal spray.
CONCLUSIONS: In participants with high hypothalamic insulin sensitivity, insulin action in the brain enhanced second-phase insulin secretion from pancreatic beta cells. This reaction could, for example, contribute to late postprandial glucose regulation by suppressing hepatic glucose production by portal venous insulin.
© 2019 S. Karger AG, Basel.

Entities:  

Keywords:  Hypothalamus; Imaging; Insulin resistance; Insulin secretion; Pancreas

Year:  2019        PMID: 31689708     DOI: 10.1159/000504551

Source DB:  PubMed          Journal:  Neuroendocrinology        ISSN: 0028-3835            Impact factor:   4.914


  7 in total

1.  Empagliflozin Improves Insulin Sensitivity of the Hypothalamus in Humans With Prediabetes: A Randomized, Double-Blind, Placebo-Controlled, Phase 2 Trial.

Authors:  Stephanie Kullmann; Julia Hummel; Robert Wagner; Corinna Dannecker; Andreas Vosseler; Louise Fritsche; Ralf Veit; Konstantinos Kantartzis; Jürgen Machann; Andreas L Birkenfeld; Norbert Stefan; Hans-Ulrich Häring; Andreas Peter; Hubert Preissl; Andreas Fritsche; Martin Heni
Journal:  Diabetes Care       Date:  2022-02-01       Impact factor: 19.112

Review 2.  Metabolic implications of pancreatic fat accumulation.

Authors:  Robert Wagner; Sabine S Eckstein; Hajime Yamazaki; Felicia Gerst; Jürgen Machann; Benjamin Assad Jaghutriz; Annette Schürmann; Michele Solimena; Stephan Singer; Alfred Königsrainer; Andreas L Birkenfeld; Hans-Ulrich Häring; Andreas Fritsche; Susanne Ullrich; Martin Heni
Journal:  Nat Rev Endocrinol       Date:  2021-10-20       Impact factor: 43.330

3.  Using nanotechnology to deliver biomolecules from nose to brain - peptides, proteins, monoclonal antibodies and RNA.

Authors:  Mireya L Borrajo; María José Alonso
Journal:  Drug Deliv Transl Res       Date:  2021-11-03       Impact factor: 4.617

4.  α-Lipoic Acid Strengthens the Antioxidant Barrier and Reduces Oxidative, Nitrosative, and Glycative Damage, as well as Inhibits Inflammation and Apoptosis in the Hypothalamus but Not in the Cerebral Cortex of Insulin-Resistant Rats.

Authors:  Mateusz Maciejczyk; Ewa Żebrowska; Miłosz Nesterowicz; Małgorzata Żendzian-Piotrowska; Anna Zalewska
Journal:  Oxid Med Cell Longev       Date:  2022-03-29       Impact factor: 6.543

5.  Comprehensive validation of fasting-based and oral glucose tolerance test-based indices of insulin secretion against gold standard measures.

Authors:  Katsiaryna Prystupa; Rebecka Renklint; Youssef Chninou; Julia Otten; Louise Fritsche; Sebastian Hoerber; Andreas Peter; Andreas L Birkenfeld; Andreas Fritsche; Martin Heni; Robert Wagner
Journal:  BMJ Open Diabetes Res Care       Date:  2022-09

6.  Type 2 diabetes risk gene Dusp8 regulates hypothalamic Jnk signaling and insulin sensitivity.

Authors:  Sonja C Schriever; Dhiraj G Kabra; Katrin Pfuhlmann; Peter Baumann; Emily V Baumgart; Joachim Nagler; Fabian Seebacher; Luke Harrison; Martin Irmler; Stephanie Kullmann; Felipe Corrêa-da-Silva; Florian Giesert; Ruchi Jain; Hannah Schug; Julien Castel; Sarah Martinez; Moya Wu; Hans-Ulrich Häring; Martin Hrabe de Angelis; Johannes Beckers; Timo D Müller; Kerstin Stemmer; Wolfgang Wurst; Jan Rozman; Ruben Nogueiras; Meri De Angelis; Jeffery D Molkentin; Natalie Krahmer; Chun-Xia Yi; Mathias V Schmidt; Serge Luquet; Martin Heni; Matthias H Tschöp; Paul T Pfluger
Journal:  J Clin Invest       Date:  2020-11-02       Impact factor: 14.808

7.  The Candidate Schizophrenia Risk Gene Tmem108 Regulates Glucose Metabolism Homeostasis.

Authors:  Jianbo Yu; Xufeng Liao; Yanzi Zhong; Yongqiang Wu; Xinsheng Lai; Huifeng Jiao; Min Yan; Yu Zhang; Chaolin Ma; Shunqi Wang
Journal:  Front Endocrinol (Lausanne)       Date:  2021-10-08       Impact factor: 5.555

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.